OPCH

Option Care Health, Inc.

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

7.5d↓-4.5%

as of 2026-09-15

News Summary

Negative

Option Care Health delivered modest Q2 2026 results with 2% YoY revenue growth and 3% YoY EBITDA growth, but guidance narrowing and multiple analyst downgrades (Stephens, Deutsche Bank) signal execution concerns and skepticism about achieving back-half growth targets. The stock has fallen 36% from its 52-week high despite mixed analyst consensus, reflecting investor concerns about the steep EBITDA ramp needed in H2 2026 and difficulty sustaining core growth.

Red flags

•Guidance narrowed (not raised) despite revenue beat, suggesting management confidence issues
•Multiple consecutive analyst downgrades (Stephens to Equal Weight, Deutsche Bank to Hold) citing execution concerns
•Stock down 36% from 52-week high of $36.80 to ~$24, indicating significant loss of investor confidence
•Steep implied H2 2026 EBITDA ramp required to hit narrowed guidance ($480–$495M annually); Q2 run-rate suggests challenge
•Q1 2026 revenue miss ($1.35B vs. guidance need) created doubt about back-half ramp; Q2 modest growth (1.9% YoY) does not fully alleviate concern
•Chronic therapies flat YoY with CID declines, indicating portfolio headwinds in core business
•Analyst commentary flags difficulty driving 21%-31% core growth without 'significant events', suggesting organic growth trajectory is challenged

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Durable Capital Partners	SC 13G/A	—	3.9%	-2.5% vs SPY -2.4% abs	2026-08-14	↗